Iantrek, a leader in bio-interventional ophthalmic surgery (BIOS), has closed a $42 million Series C financing round. These funds will support the U.S. launch of AlloFlo Uveo, a novel surgical solution targeting the uveoscleral pathway, and will help expand the company’s product pipeline. The Series C was led by U.S. Venture Partners (USVP), with participation from aMoon Fund and existing investors, including Visionary Ventures and Sectoral Asset Management.
Glaucoma is a chronic eye disease that can lead to irreversible optic nerve damage and vision loss. Treatment typically aims to reduce intraocular pressure (IOP) by either improving aqueous drainage or decreasing its production. In healthy eyes, there are two primary pathways for regulating aqueous drainage: the trabecular and uveoscleral pathways. While most current minimally invasive glaucoma surgery (MIGS) devices focus on the trabecular pathway, Iantrek’s BIOS platform introduces a minimally invasive option for accessing the uveoscleral pathway, which has long been targeted by medications but has lacked effective surgical solutions.
In a 2025 study published in Ophthalmology Science by the American Academy of Ophthalmology, AlloFlo Uveo demonstrated long-lasting efficacy and safety after two years. Key results included a 34% mean reduction in IOP, more than 60% decrease in the usage of IOP-lowering medications, and no serious product-related adverse events.
Iantrek’s portfolio includes AlloFlo Uveo, AlloSert Uveo, and C.Rex—innovative bio-interventional solutions designed to enhance surgical precision and access to the eye’s natural drainage pathways. AlloFlo Uveo is the first allogeneic graft designed for long-lasting implantation and bio-integration in ophthalmic procedures. The company has also completed initial human trials for a new bio-interventional product, with a commercial launch expected in 2026.
KEY QUOTES:
“Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it. More than 2.5 million eyes in the U.S. are experiencing waning efficacy from previous Minimally Invasive Glaucoma Surgery (MIGS) procedures targeting the trabecular pathway. AlloFlo Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system—much like giving a thoracic surgeon the ability to enhance the second lung.”
Adam Szaronos, CEO of Iantrek
“This raise reflects strong confidence in Iantrek’s bold vision and disruptive approach to interventional glaucoma. Their platform is redefining what’s possible by combining simplicity, precision, and improved outcomes.”
Casey Tansey, General Partner at USVP
“With approximately 3,000 procedures performed through its early access program, surgeon demand for uveoscleral pathway access is clear.”
“Iantrek’s bio-interventional approach is currently the only surgical solution targeting this major outflow pathway with the highest therapeutic index in glaucoma treatment.”
Sean Ianchulev, MD, MPH, Professor of Ophthalmology at the New York Eye and Ear of Mount Sinai and Chairman of the Board of Iantrek
“Iantrek’s sophisticated solution delivers significant clinical value and provides a new minimally invasive option for patients with glaucoma. We are looking forward to working with Adam Szaronos, Dr. Sean Ianchulev, and the whole team on their mission to provide next-generation glaucoma treatment to the many thousands of patients in need.”
Todd Sone, General Partner at aMoon Fund
